Evidence map›Paper›PMID 39718121›Full record

ArticleJournal of pediatric gastroenterology and nutrition2025

Long-term outcome of pediatric acute severe colitis: A prospective 5-year follow-up of the PRASCO trial.

Dan Lachman, Esther Orlanski-Meyer, Raffi Lev-Tzion, Oren Ledder, Amit Assa, Zivia Shavit-Brunschwig, Baruch Yerushalmi, Marina Aloi, Anne M Griffiths, Lindsey Albenberg and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pediatric gastroenterology and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Dan LachmanJuliet Keidan Institute of Pediatric Gastroenterology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.ORCID 0009-0004-0333-9947
Esther Orlanski-MeyerJuliet Keidan Institute of Pediatric Gastroenterology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
Raffi Lev-TzionJuliet Keidan Institute of Pediatric Gastroenterology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
Oren LedderJuliet Keidan Institute of Pediatric Gastroenterology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
Amit AssaJuliet Keidan Institute of Pediatric Gastroenterology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
Zivia Shavit-BrunschwigJuliet Keidan Institute of Pediatric Gastroenterology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
Baruch YerushalmiPediatric Gastroenterology Unit, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Marina AloiSapienza University of Rome, Rome, Italy.
Anne M GriffithsThe Hospital for Sick Children (SickKids), Toronto, Canada.
Lindsey AlbenbergThe Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, USA.
Itzhak Bar-OrWolfson Medical Center, Holon, Israel.
Kaija-Leena KolhoHospital for Children and Adolescents, Children's Hospital, Helsinki University, Helsinki, Finland.
Dror S ShouvalInstitute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petah Tikvah, Israel.
Shlomi CohenDana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, The Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Dan TurnerJuliet Keidan Institute of Pediatric Gastroenterology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.ORCID 0000-0001-5160-868X
Ohad AtiaJuliet Keidan Institute of Pediatric Gastroenterology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.ORCID 0000-0001-7800-1984

Funding

Helmsley Charitable Trust, the International Organization of IBD (IOIBD)Helmsley Charitable Trust, the International Organization of IBD (IOIBD); Janssen Educational Grant
6 · The paper itself

Abstract

objectivesThe PRASCO trial reported the short-term superiority of an antibiotic cocktail plus intravenous corticosteroids (IVCS) over IVCS alone in children with acute severe colitis (ASC). Here, we report the extension of the PRASCO trial and the long-term outcomes of the antibiotic cocktail in ASC.

methodsThis prospective follow-up of the PRASCO trial documented disease outcomes and treatments annually through 5 years. The primary outcome was colectomy, and the secondary outcome was escalation to biologics, analyzed descriptively.

resultsA total of 26 children were included (12 receiving IVCS and 14 receiving IVCS + antibiotics), 19% of whom underwent colectomy during the follow-up period. The estimated probability of colectomy at 3, 6, and 12 months from admission were 7.1%, 7.1%, and 21% with IVCS + antibiotics and 0%, 8.3%, and 17% with IVCS. No children required colectomy after the first year of follow-up. The estimated probability of escalating to biologics were 66%, 77%, and 77% after 1, 2, and 3 years with IVCS + antibiotics and 42%, 51%, and 76% with IVCS. Clinical remission was higher in the IVCS + antibiotics group at each timepoint (e.g., 30% vs. 11% at 5-years). Delta of Pediatric Ulcerative Colitis Activity Index (PUCAI) score from baseline to day three of admission predicted future escalation to biologics (area under curves (AUC) 0.84 [95%CI 0.59-1.0]).

conclusionWhile adding antibiotics to IVCS may provide better short-term outcomes, the long-term benefits were comparable to IVCS alone. At 5 years, about one-fifth of children had undergone colectomy, and almost four-fifths had escalated to biologics, particularly during the first year after admission.

Indexed as

Adrenal Cortex HormonesAnti-Bacterial AgentsColitisAcute DiseaseAdolescentChildChild, PreschoolColectomyDrug Therapy, CombinationFemaleFollow-Up StudiesHumansMaleProspective StudiesSeverity of Illness IndexTreatment OutcomeAdrenal Cortex HormonesAnti-Bacterial Agentsacute severe colitisantibioticbiologic escalationpediatric

Identifiers

PMID39718121
PMCPMC11874199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.